 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...156157158159160161162163164165166...170171» |
- | rivaroxaban / Bayer, Generic mfg.
Journal: Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy - A Single Center Registry. (Pubmed Central) - May 11, 2017
The "real world" effectiveness and safety of rivaroxaban is similar for venous thromboembolism patients with and without active malignancy.
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: MARINER: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (clinicaltrials.gov) - May 10, 2017
P3, N=12000, Recruiting, Sponsor: Janssen Research & Development, LLC
The "real world" effectiveness and safety of rivaroxaban is similar for venous thromboembolism patients with and without active malignancy. Trial primary completion date: Feb 2018 --> May 2018
- || rivaroxaban / Generic mfg.
Trial primary completion date: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (clinicaltrials.gov) - May 9, 2017
P4, N=253, Recruiting, Sponsor: RWTH Aachen University
Trial primary completion date: Feb 2018 --> May 2018 Trial primary completion date: Jan 2016 --> Dec 2017
- || rivaroxaban / Generic mfg.
Trial primary completion date: Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (clinicaltrials.gov) - May 8, 2017
P=N/A, N=99999, Recruiting, Sponsor: Bayer
Trial primary completion date: Jan 2016 --> Dec 2017 Trial primary completion date: Apr 2017 --> Sep 2017
- | rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
Review, Journal: A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. (Pubmed Central) - May 8, 2017
Extended therapy trials have consistently demonstrated superior effectiveness for DOAC treatment when compared with placebo in preventing VTE recurrence. This article presents a comprehensive review of the pharmacokinetics, pharmacodynamics and accumulated clinical trial evidence for each DOAC for short-term, long-term and extended VTE therapy, and it considers the potential implications these agents have for the clinical management of VTE.
- | rivaroxaban / Generic mfg.
Trial completion, Enrollment change: EINSTEINJr: EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (clinicaltrials.gov) - May 5, 2017
P2, N=47, Completed, Sponsor: Bayer
This article presents a comprehensive review of the pharmacokinetics, pharmacodynamics and accumulated clinical trial evidence for each DOAC for short-term, long-term and extended VTE therapy, and it considers the potential implications these agents have for the clinical management of VTE. Recruiting --> Completed | N=20 --> 47
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Use of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Before Stroke. (Pubmed Central) - May 5, 2017
Although experience of using rt-PA in patients with ischemic stroke on a NOAC is limited, these preliminary observations suggest that rt-PA appears to be reasonably well tolerated without prohibitive risks for adverse events among selected NOAC-treated patients. Future studies should evaluate the safety and efficacy of intravenous rt-PA in patients with ischemic stroke who are taking NOACs.
- | rivaroxaban / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: RIDTS: Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis (clinicaltrials.gov) - May 4, 2017
P3, N=1100, Recruiting, Sponsor: Walter Ageno
Future studies should evaluate the safety and efficacy of intravenous rt-PA in patients with ischemic stroke who are taking NOACs. Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
New P2 trial, Metastases: PRIORITY: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism (clinicaltrials.gov) - May 4, 2017
P2, N=176, Recruiting, Sponsor: Asan Medical Center
- || Xarelto (rivaroxaban) / J&J
Trial primary completion date, Surgery: Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) - May 3, 2017
P=N/A, N=100, Recruiting, Sponsor: Matthew Neal MD
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Mar 2017 --> Mar 2018
- | Xarelto (rivaroxaban) / J&J
Trial primary completion date: Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study (clinicaltrials.gov) - May 3, 2017
P3, N=100, Recruiting, Sponsor: Universit
Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Jun 2018 --> Jun 2019
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial primary completion date: TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) - May 3, 2017
P3, N=536, Recruiting, Sponsor: University of Padova
Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Dec 2018 --> Dec 2020
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. (Pubmed Central) - May 3, 2017
Trial primary completion date: Dec 2018 --> Dec 2020 We found that dose-adjusted DOAC therapy was often prescribed in a dose that was lower than package insert recommendations.
- |||| rivaroxaban / Generic mfg.
Trial completion: MERCURY PE: A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (clinicaltrials.gov) - May 1, 2017
P4, N=114, Completed, Sponsor: Janssen Scientific Affairs, LLC
We found that dose-adjusted DOAC therapy was often prescribed in a dose that was lower than package insert recommendations. Active, not recruiting --> Completed
- | Savaysa (edoxaban) / Daiichi Sankyo
New P4 trial: DANNOAC-AF: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (clinicaltrials.gov) - Apr 26, 2017
P4, N=11000, Not yet recruiting, Sponsor: Danish Heart Foundation
- | Savaysa (edoxaban) / Daiichi Sankyo
New P4 trial: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (clinicaltrials.gov) - Apr 26, 2017
P4, N=5000, Not yet recruiting, Sponsor: Danish Heart Foundation
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
New trial: Use of Direct Oral Anticoagulants in UK (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=3000, Not yet recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Biomarker, New trial: DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=350, Not yet recruiting, Sponsor: University Hospital, Geneva
- |||| rivaroxaban / Generic mfg.
Clinical data, Trial primary completion date: GALILEO: Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (clinicaltrials.gov) - Apr 12, 2017
P3, N=1520, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Jul 2018 --> Nov 2018
- ||||| rivaroxaban / Generic mfg.
Enrollment change: MARINER: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (clinicaltrials.gov) - Apr 11, 2017
P3, N=12000, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2018 --> Nov 2018 N=8000 --> 12000
- | rivaroxaban / Generic mfg.
Trial completion, Surgery, Bariatric surgery: PK of Rivaroxaban in Bariatric Patients - Extension (clinicaltrials.gov) - Apr 11, 2017
P1, N=13, Completed, Sponsor: University Hospital Inselspital, Berne
N=8000 --> 12000 Active, not recruiting --> Completed
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: CASSINI: A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants (clinicaltrials.gov) - Apr 10, 2017
P3, N=700, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> Jul 2018
- | Xarelto (rivaroxaban) / J&J, aspirin / Generic mfg., warfarin / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, HEOR: PEPPER: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (clinicaltrials.gov) - Apr 10, 2017
P4, N=25000, Recruiting, Sponsor: Medical University of South Carolina
Trial primary completion date: Jan 2018 --> Jul 2018 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 | Trial primary completion date: Mar 2020 --> Aug 2020
- || rivaroxaban / Generic mfg.
Enrollment change: Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children (clinicaltrials.gov) - Apr 6, 2017
P1, N=58, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 | Trial primary completion date: Mar 2020 --> Aug 2020 N=48 --> 58
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Enrollment closed, Trial initiation date, Trial primary completion date: COBRRA Pilot: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban (clinicaltrials.gov) - Apr 5, 2017
P4, N=72, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
N=48 --> 58 Recruiting --> Active, not recruiting | Initiation date: Jan 2016 --> May 2016 | Trial primary completion date: Jan 2017 --> Sep 2017
- ||||| rivaroxaban / Generic mfg.
Enrollment closed, Trial primary completion date: COMPASS: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (clinicaltrials.gov) - Apr 4, 2017
P3, N=27395, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Initiation date: Jan 2016 --> May 2016 | Trial primary completion date: Jan 2017 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> May 2017
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment open, Retrospective data: The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=47000, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> May 2017 Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg., atorvastatin / Generic mfg., warfarin / Generic mfg.
Trial primary completion date: Statin Use in Patients With Acute VTE (clinicaltrials.gov) - Mar 29, 2017
P1/2, N=80, Recruiting, Sponsor: Ohio State University
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Jan 2018
- || Trial primary completion date: AtriClip (clinicaltrials.gov) - Mar 29, 2017
P4, N=2000, Recruiting, Sponsor: AtriCure, Inc.
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Aug 2018 --> Nov 2019
- ||| rivaroxaban / Generic mfg.
New trial: Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=1000, Recruiting, Sponsor: Nihon University
- | rivaroxaban / Generic mfg.
Journal: Determinants of Heparin Dosing and Complications in Patients Undergoing Left Atrial Ablation on Uninterrupted Rivaroxaban. (Pubmed Central) - Mar 25, 2017
A heparin dose of 120 units/kg achieves an ACT > 300 seconds in the majority of patients. In cases of pericardial effusion, bleeding may be prolonged.
- rivaroxaban / Generic mfg.
Enrollment change, Trial withdrawal, Surgery: VeriXAPPORT: Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: Bayer
In cases of pericardial effusion, bleeding may be prolonged. N=100 --> 0 | Not yet recruiting --> Withdrawn
- |||| aspirin / Generic mfg.
Enrollment open: STROKE-VT: DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation (clinicaltrials.gov) - Mar 24, 2017
P4, N=110, Recruiting, Sponsor: Dhanunjaya Lakkireddy, MD, FACC
N=100 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Mar 20, 2017
P3, N=270, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Jul 2019
- ||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
New P1 trial: A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa (clinicaltrials.gov) - Mar 19, 2017
P1, N=77, Recruiting, Sponsor: Portola Pharmaceuticals
- ||| Savaysa (edoxaban) / Daiichi Sankyo
Trial completion: PRiSMA-AF: Atrial Fibrillation Patient Preference Study (clinicaltrials.gov) - Mar 17, 2017
P=N/A, N=382, Completed, Sponsor: Bayer
Trial primary completion date: Jul 2018 --> Jul 2019 Active, not recruiting --> Completed
- ||| rivaroxaban / Generic mfg.
Trial completion, HEOR, Real-world evidence, Real-world: Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=99999, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Phase classification, Retrospective data: The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=47000, Not yet recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Trial primary completion date: ADAGE: New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=225, Recruiting, Sponsor: H
Phase classification: P4 --> P=N/A Trial primary completion date: Jul 2016 --> Jul 2017
- ||||| rivaroxaban / Generic mfg.
Enrollment closed, Surgery: ESPER: Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban (clinicaltrials.gov) - Mar 6, 2017
P3, N=231, Active, not recruiting, Sponsor: University Hospital, Brest
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Active, not recruiting
- | rivaroxaban / Generic mfg.
New P1 trial: Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany) (clinicaltrials.gov) - Mar 6, 2017
P1, N=24, Completed, Sponsor: Genuine Research Center, Egypt
- | rivaroxaban / Generic mfg., diclofenac potassium oral solution / Generic mfg.
Journal: Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: A case report. (Pubmed Central) - Feb 27, 2017
Despite the ingestion of a massive amount of rivaroxaban, the plasma levels were not as high as feared, due to the ceiling effect of rivaroxaban absorption. Elimination occurred according to the half-life of rivaroxaban and was not unduly prolonged by the ingested quantity.
- |||| Trial completion: GEMINI ACS 1: A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (clinicaltrials.gov) - Feb 23, 2017
P2, N=3039, Completed, Sponsor: Janssen Research & Development, LLC
Elimination occurred according to the half-life of rivaroxaban and was not unduly prolonged by the ingested quantity. Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Trial primary completion date: X-PRESS: Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=300, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Dec 2017
- || Savaysa (edoxaban) / Daiichi Sankyo
Enrollment closed: PRiSMA-AF: Atrial Fibrillation Patient Preference Study (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=382, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- Xience (everolimus-eluting stent) / Abbott
Enrollment change, Trial withdrawal, Cost of therapy: COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials (clinicaltrials.gov) - Feb 20, 2017
P4, N=0, Withdrawn, Sponsor: IHF GmbH - Institut f
Recruiting --> Active, not recruiting N=900 --> 0 | Not yet recruiting --> Withdrawn
- ||| rivaroxaban / Generic mfg.
Trial completion: XALIA LEA: Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (clinicaltrials.gov) - Feb 17, 2017
P=N/A, N=1989, Completed, Sponsor: Bayer
N=900 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg.
New P3 trial, Surgery: PRO-LAPSII: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. (clinicaltrials.gov) - Feb 16, 2017
P3, N=646, Not yet recruiting, Sponsor: Fadoi Foundation, Italy
- ||| rivaroxaban / Generic mfg.
Trial completion, Trial primary completion date: Validation of Rivaroxaban Assay for US Registration (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=100, Completed, Sponsor: Diagnostica Stago
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2016
- | rivaroxaban / Generic mfg.
Phase classification, Surgery: VeriXAPPORT: Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2016 Phase classification: P4 --> P=N/A